A prespecified analysis of the DAPA-CKD trial has reported that dapagliflozin significantly reduced albuminuria (reduction in urinary albumin-to-creatinine ratio by 29.3% (95% CI, (-33.1 to -25.2)); p < 0.0001) in individuals with T2D [92]. This evidence concerns the gene ALB and chronic kidney disease.